[Anaemia, cardiac failure and erythropoietin].
Anaemia is common in severe cardiac failure due to systolic dysfunction. The mechanisms are varied. Anaemia is a negative prognostic factor. Treatment with erythropoietin seems to improve the quality of life, functional status, effort tolerance and systolic function of these patients. Large scale clinical trials are on-going.
Cohen Solal
A
A
Service de cardiologie, hôpital Beaujon, Clichy.
Beauvais
F
F
D000740:Anemia / Q000188:drug therapy / Q000209:etiology*; D004921:Erythropoietin / Q000502:physiology* / Q000627:therapeutic use; D006331:Heart Diseases / Q000503:physiopathology*; D006333:Heart Failure / Q000503:physiopathology; D006801:Humans; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin